Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John James Sullivan sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $138.00, for a total transaction of $552,000.00. Following the sale, the director now directly owns 72,248 shares of the company’s stock, valued at $9,970,224. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Mesa Laboratories, Inc. (MLAB) opened at $137.51 on Thursday. Mesa Laboratories, Inc. has a 12 month low of $117.58 and a 12 month high of $169.80. The company has a quick ratio of 1.64, a current ratio of 2.37 and a debt-to-equity ratio of 0.58. The company has a market cap of $516.93, a P/E ratio of -137.51 and a beta of 0.52.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Wednesday, February 28th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.47%. The ex-dividend date of this dividend is Tuesday, February 27th. Mesa Laboratories’s payout ratio is presently -64.00%.
Large investors have recently modified their holdings of the business. Capital Analysts LLC bought a new stake in Mesa Laboratories in the third quarter valued at approximately $128,000. SG Americas Securities LLC bought a new stake in Mesa Laboratories in the third quarter valued at approximately $131,000. MetLife Investment Advisors LLC bought a new stake in Mesa Laboratories in the fourth quarter valued at approximately $183,000. Voya Investment Management LLC bought a new stake in Mesa Laboratories in the second quarter valued at approximately $221,000. Finally, Westfield Capital Management Co. LP bought a new stake in Mesa Laboratories in the third quarter valued at approximately $239,000. 72.77% of the stock is owned by hedge funds and other institutional investors.
MLAB has been the subject of a number of recent research reports. TheStreet raised shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research note on Monday, November 6th. Zacks Investment Research downgraded shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Friday, November 10th. Finally, BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/22/john-james-sullivan-sells-4000-shares-of-mesa-laboratories-inc-mlab-stock.html.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.